Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCED9U)

Drug Name

IRX-5183 Drug Info

Synonyms

AGN-195183; NRX-195183; NRX-5183; VTP-195183; VTP-5183; IRX-5183 (oral, autoimmune disease), Io Therapeutics; RARa (oral, cancer/autoimmune disease), Io Therapeutics; RARa agonist (topical, skin/eye diseases), Io Therapeutics; Retinoic acid receptor alpha agonist (oral, cancer/autoimmune disease), Io Therapeutics; Retinoic acid receptor alpha agonist (topical, skin/eye diseases), Io Therapeutics; IRX-5183 (oral, cancer/autoimmune disease), Io Therapeutics; IRX-5183 (topical, skin/eye diseases), Io Therapeutics

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

PubChem CID: 9867758
ChEBI ID: CHEMBL107430
CAS Number: CAS 367273-07-2
TTD Drug ID: DMCED9U

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Retinoic acid receptor alpha (RARA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tamibarotene	DM3G74J	T-cell leukaemia	2A90	Phase 3	[3]
SY-1425	DMH8UF0	Acute myeloid leukaemia	2A60	Phase 1	[1]
PMID27336223-Compound-4	DMJFSOM	N. A.	N. A.	Patented	[4]
PMID27336223-Compound-5	DM6E50A	N. A.	N. A.	Patented	[4]
LG100268	DM41RK2	Acquired immune deficiency syndrome	1C62.3	Discontinued in Phase 1	[5]
CD666	DMC8X9Y	Discovery agent	N.A.	Investigative	[6]
AGN193109	DMC0YOE	Discovery agent	N.A.	Investigative	[7]
AGN193836	DMEB93D	Discovery agent	N.A.	Investigative	[8]
BMS614	DMZWNO9	Discovery agent	N.A.	Investigative	[9]
Ro-40-0655	DM8PYAN	Colorectal cancer	2B91.Z	Investigative	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Retinoic acid receptor RXR (RXR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IRX4204	DM9SCME	Breast cancer	2C60-2C65	Phase 1	[1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Retinoic acid receptor alpha (RARA)	TTW38KT	RARA_HUMAN	Agonist	[2]
Retinoic acid receptor RXR (RXR)	TTP7WQM	NOUNIPROTAC	Agonist	[1]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Retinoic acid receptor alpha and retinoid X receptor specific agonists reduce renal injury in established chronic glomerulonephritis of the rat. J Mol Med (Berl). 2004 Feb;82(2):116-25.
3	Tamibarotene: a candidate retinoid drug for Alzheimer's disease. Biol Pharm Bull. 2012;35(8):1206-12.
4	Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71.
5	Placental steroidogenesis in rats is independent of signaling pathways induced by retinoic acids. Gen Comp Endocrinol. 2009 Sep 15;163(3):285-91.
6	Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor gamma. Biochem Biophys Res Commun. 1992 Jul 31;186(2):977-83.
7	Therapeutic applications for ligands of retinoid receptors. Curr Pharm Des. 2000 Jan;6(1):25-58.
8	Synthesis and biological activity of retinoic acid receptor-alpha specific amides. Bioorg Med Chem Lett. 2002 Nov 4;12(21):3145-8.
9	Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. Nature. 2002 Jan 10;415(6868):187-92.
10	Tamibarotene. Drugs Today (Barc). 2007 Aug;43(8):563-8.